| [Relationship between DTA Mutations and Thromboembolism in Patients with Myeloproliferative Neoplasms]. | [Relationship between DTA Mutations and Thromboembolism in Patients with Myeloproliferative Neoplasms].
Wang M, Zhao HY, Li DQ, Chen P. | 07/16/2024 |
| Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119. | Human ASXL1-Mutant Hematopoiesis Is Driven by a Truncated Protein Associated with Aberrant Deubiquitination of H2AK119.
Köhnke T, Nuno KA, Alder CC, Gars EJ, Phan P, Fan AC, Majeti R., Free PMC Article | 05/3/2024 |
| Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study. | Clonal haematopoiesis of indeterminate potential and atrial fibrillation: an east Asian cohort study.
Ahn HJ, An HY, Ryu G, Lim J, Sun C, Song H, Choi SY, Lee H, Maurer T, Nachun D, Kwon S, Lee SR, Lip GYH, Oh S, Jaiswal S, Koh Y, Choi EK. | 04/17/2024 |
| Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms. | Altered erythropoiesis via JAK2 and ASXL1 mutations in myeloproliferative neoplasms.
Collins TB, Laranjeira ABA, Kong T, Fulbright MC, Fisher DAC, Sturgeon CM, Batista LFZ, Oh ST., | 04/3/2024 |
| Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms. | Comprehensive genomic profiling reveals molecular subsets of ASXL1-mutated myeloid neoplasms.
Johnson SM, Haberberger J, Galeotti J, Ramkissoon L, Coombs CC, Richardson DR, Foster MC, Duncan D, Montgomery ND, Ferguson NL, Zeidner JF. | 01/30/2024 |
| ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms. | ASXL1 mutation is a novel risk factor for bleeding in Philadelphia-negative myeloproliferative neoplasms.
Awada H, Bhatta M, Yu H, Ji W, Hou S, Cronin T, Ba Aqeel S, Roy AM, Faisal MS, Kouides P, Mascarenhas J, Griffiths EA, Elshoury A. | 01/12/2024 |
| Targeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical models. | Targeting lysine demethylase 6B ameliorates ASXL1 truncation-mediated myeloid malignancies in preclinical models.
Ge G, Zhang P, Sui P, Chen S, Yang H, Guo Y, Rubalcava IP, Noor A, Delma CR, Agosto-Peña J, Geng H, Medina EA, Liang Y, Nimer SD, Mesa R, Abdel-Wahab O, Xu M, Yang FC., Free PMC Article | 01/8/2024 |
| Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis. | Prognostic value of ASXL1 mutations in patients with myelodysplastic syndromes and acute myeloid leukemia: A meta-analysis.
Zhang A, Wang S, Ren Q, Wang Y, Jiang Z. | 09/26/2023 |
| Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1. | Structural basis of histone H2A lysine 119 deubiquitination by Polycomb repressive deubiquitinase BAP1/ASXL1.
Thomas JF, Valencia-Sánchez MI, Tamburri S, Gloor SL, Rustichelli S, Godínez-López V, De Ioannes P, Lee R, Abini-Agbomson S, Gretarsson K, Burg JM, Hickman AR, Sun L, Gopinath S, Taylor HF, Sun ZW, Ezell RJ, Vaidya A, Meiners MJ, Cheek MA, Rice WJ, Svetlov V, Nudler E, Lu C, Keogh MC, Pasini D, Armache KJ., Free PMC Article | 08/11/2023 |
| Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression. | Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression.
Yan X, Xu Z, Zhang P, Sun Q, Jia Y, Qin T, Qu S, Pan L, Li Z, Liu J, Song Z, Gao Q, Jiao M, Gong J, Wang H, Li B, Xiao Z., Free PMC Article | 08/10/2023 |
| Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia. | Co-occurring mutations in ASXL1, SRSF2, and SETBP1 define a subset of myelodysplastic/ myeloproliferative neoplasm with neutrophilia.
Jain T, Ware AD, Dalton WB, Pasca S, Tsai HL, Gocke CD, Gondek LP, Xian RR, Borowitz MJ, Levis MJ. | 08/2/2023 |
| Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome. | Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.
Feng Y, Liang H, Han M, Luo X, Zhu Y, Liu B. | 06/9/2023 |
| Epigenetic regulation by ASXL1 in myeloid malignancies. | Epigenetic regulation by ASXL1 in myeloid malignancies.
Yang FC, Agosto-Peña J. | 05/30/2023 |
| Basis of the H2AK119 specificity of the Polycomb repressive deubiquitinase. | Basis of the H2AK119 specificity of the Polycomb repressive deubiquitinase.
Ge W, Yu C, Li J, Yu Z, Li X, Zhang Y, Liu CP, Li Y, Tian C, Zhang X, Li G, Zhu B, Xu RM. | 04/15/2023 |
| Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. | Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia.
Bidikian A, Kantarjian H, Jabbour E, Short NJ, Patel K, Ravandi F, Sasaki K, Issa GC., Free PMC Article | 11/5/2022 |
| The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing. | The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing.
Xu J, Hao Z, Chen X, Hong M, Muyey DM, Chen X, Wang H. | 10/15/2022 |
| Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis. | Prognostic value of ASXL1 mutations in acute myeloid leukemia: A meta-analysis.
Lipilkin PV, Kulaeva ED, Mashkina EV. | 09/10/2022 |
| ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera. | ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera.
Guglielmelli P, Coltro G, Mannelli F, Rotunno G, Loscocco GG, Mannarelli C, Maccari C, Paoli C, Romagnoli S, Bartalucci N, Vannucchi AM., Free PMC Article | 07/30/2022 |
| Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran. | Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran.
Parsa-Kondelaji M, Ayatollahi H, Rostami M, Sheikhi M, Barzegar F, Afzalaghaee M, Moradi E, Sadeghian MH, Momtazi-Borojeni AA., Free PMC Article | 07/16/2022 |
| Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia. | Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
Wang L, Birch NW, Zhao Z, Nestler CM, Kazmer A, Shilati A, Blake A, Ozark PA, Rendleman EJ, Zha D, Ryan CA, Morgan MAJ, Shilatifard A. | 05/7/2022 |
| Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A single-center study. | Clinical implication and prognostic significance of FLT3-ITD and ASXL1 mutations in Egyptian AML patients: A single-center study.
Ebian HF, Elshorbagy S, Mohamed H, Embaby A, Khamis T, Sameh R, Sabbah NA, Hussein S. | 04/30/2022 |
| ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome. | ASXL1 and STAG2 are common mutations in GATA2 deficiency patients with bone marrow disease and myelodysplastic syndrome.
West RR, Calvo KR, Embree LJ, Wang W, Tuschong LM, Bauer TR, Tillo D, Lack J, Droll S, Hsu AP, Holland SM, Hickstein DD., Free PMC Article | 04/23/2022 |
| Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia. | Oncogenic gene expression and epigenetic remodeling of cis-regulatory elements in ASXL1-mutant chronic myelomonocytic leukemia.
Binder M, Carr RM, Lasho TL, Finke CM, Mangaonkar AA, Pin CL, Berger KR, Mazzone A, Potluri S, Ordog T, Robertson KD, Marks DL, Fernandez-Zapico ME, Gaspar-Maia A, Patnaik MM., Free PMC Article | 04/9/2022 |
| High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients. | High Frequency of ASXL1 and IDH Mutations in Young Acute Myeloid Leukemia Egyptian Patients.
El Nahass YH, Nader HA, Sabet S, Nooh HA, Bassiony H, Kamel M, Samra MA, Mahmoud HK, El Metnawy WH, El Refaey FA., Free PMC Article | 04/2/2022 |
| The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis. | The prognostic value of the interaction between ASXL1 and TET2 gene mutations in patients with chronic myelomonocytic leukemia: a meta-analysis.
Zhao W, Zhang C, Li Y, Li Y, Liu Y, Sun X, Liu M, Shao R. | 03/26/2022 |